Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
Minoo Mohraz(Iranian Institute for Health Sciences Research), Hamed Hosseini(Tehran University of Medical Sciences), Negar Rezaei(Tehran University of Medical Sciences), Payam Tabarsi(Masih Daneshvari Hospital), Mohsen Abbasi‐Kangevari(Tehran University of Medical Sciences), Naser Ahmadi(Tehran University of Medical Sciences), Sahar Saeedi Moghaddam(Kiel Institute for the World Economy), Seyyed‐Hadi Ghamari(Shahid Beheshti University of Medical Sciences), Mojtaba Nasiri(Tehran University of Medical Sciences), Mohammadreza Salehi(Tehran University of Medical Sciences), Mohammad‐Reza Malekpour(Tehran University of Medical Sciences), Erfan Ghasemi(Tehran University of Medical Sciences), Ali Akbar Amirzargar(Tehran University of Medical Sciences), Maryam Amini Pouya(Isfahan University of Medical Sciences), Kazem Heidari(Tehran University of Medical Sciences), Bagher Larijani(Tehran University of Medical Sciences)
Cited by 16
Related Papers
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet|2020|19.7k
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet|2020|9.8k
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet Neurology|2021|7.9k